 Leverkusen, Germany, Dec. 07, 2020 GLOBE NEWSWIRE -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F, and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Sweden, Norway, Denmark, Finland and Iceland. 